Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual MeetingAccesswire • 02/09/22
Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings UpdateAccesswire • 02/08/22
Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)Accesswire • 08/30/21
Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public OfferingAccesswire • 08/20/21
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings UpdateAccesswire • 08/16/21
Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform TechnologyAccesswire • 06/08/21
Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings UpdateAccesswire • 05/17/21
Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)Accesswire • 05/10/21